The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
“Lung cancer pill halves risk of death after surgery”
This is in today’s Times. Quotes study done in Chicago. There is no mention of savo in the article as the study was conducted using only Tagrisso or Placebo. Anyone able to write about Tagrisso + savo combination study and details of licensing arrangements?
Appears the IR department exists only on the paper. They have zero concern about the investing community. They have not issued any statement about the poor share price. Information available about holders of 0013.HK. shows that 46% of the total shares and 83% of the float are held by institutional shareholders. Not sure if they are in touch with the board. Is there an Asia (HK / China) based) based English discussion forum for HK listings, similar to this lse site? It will be helpful to read messages regarding HCM from the investing community based over there. Surely they must be more aggrieved having lost 70% of their investments.
Thank you pencil. Let us keep our fingers crossed and hope this development bodes well for HCM. IR department should be proactive if they want to attract such investors. A statement like “We are unable to explain the present the decline in share price. Everything is moving as per our targets” would surely bring back the confidence.
Davey, loss of 70% of investment must be really hurting. Wondering about the opinions being expressed by investors in HK and mainland China. Is anyone over there raising questions about this utterly poor share price in spite of achievements in sales, licensing deal with Takeda, last week’s FDA approval for NDA review and the pipeline. As expressed on this forum, if short sellers are responsible for this kind of fall of share price, is it not the duty of the company’s IR office to come out with a statement to pacify the investors.
The management are totally unconcerned about the market valuation. What are the institutional investors doing? Have they raised any questions?
Do the chinese investors, if any, still consider number 13 as auspicious? Here is an example to prove it otherwise.
what’s wrong with this stock?? gone down at hkse. never fails to disappoint, in spite of the fru*****inib nda news. are there any ulterior motives to make all holders to give up? takeda might have taken over the whole company by adding some extra change to the ex-china fru*****inib license deal.
Two important points regarding this NDA;
1. Going along with Takeda, a well established pharmaceutical company.
2. Supporting evidence includes “…FRESCO-2 is a global Phase III multi-regional clinical trial (MRCT) conducted in the U.S., Europe, Japan and Australia…”.
After the bad experience with Surufatinib, much better approach by the management. Well done.
It’s difficult to accurately identify if a trade is a sell or a buy. Websites like this make a guesstimate before marking the sales red or blue depending on the market quote. However, its quite worrying to see the sp dropping at all three exchanges since yesterday. Yesterday, during the first hour of trading at HKSE, sp spiked above 26 HK dollars. Following that period, it’s been red throughout.
Retrospectively, we can see one big mistake that happened while applying to the FDA for approval for Surufatinib, Clinical research data from studies which didn’t have any American patient population and going “solo”. That Failure (purely due to inexperience) at that significant moment lead to continuous downward spiral and the CEO “retiring” suddenly. A collaboration with another major player, would have provided the required preparation, knowledge and expertise while making that application. Hopefully, the ongoing “multi centre” studies are going in the correct direction and the management will get a major player on their side during the re-application process. Needless to say FDA has to be very cautious while approving a new therapy developed by a smaller pharmaceutical company based in China. The same would be different if the application also included an established major pharma.
What is on the agenda for this Friday’s AGM? Hopefully, there will be some good things to cheer up us, the longstanding (suffering) investors. Cornerstone investors who pumped vast sums of money should get more proactive. Let us se what comes out from the AGM.
I think it was Lauders who wrote here, few days ago, how badly the company has been missing a charismatic CEO like CH. 100% correct. Especially, at a time when a major pharma like AZN is talking about “making in China” that too in oncology sector. There are few posts about the value of HCM, in case of takeover or merger. Just one single drug’s (Fru*****inib) ex-China licence is worth nearly $1.4 billion. How much is it for the whole company? Major investors bought several millions of stocks paying more than the present sp. As per the previous post, they are still holding their shares. That is one bit of comforting matter.
Another encouraging news, acceptance for Fruquintinib as second line of therapy for gastric carcinoma. Takeda should certainly like to get approval for the same indication, ex-Chaina. Takeda management must have done a thorough study before going for the agreement with HCM for the ex-china license for Fruquintinib. That single agreement has a potential income of around $1.4 billion to HCM. Isn’t it intriguing why Takeda (or any other major pharma) should not be making a bid for the whole company? An offer of 5 times today’s market cap still comes to $ 15 billion. All the encouraging news about involvement of major players in China related business opportunities is indeed making long term investors more optimistic!
Management might have selected the auspicious New year day for announcing the Takeda deal. Not a great deal of enthusiastic response shown at NYSE, for a deal worth one billion, during last 3 days of trading. Has this ‘sub optimal’ nyse reaction affected HKSE when it reopened today after the holidays?
Suppose the same deal was announced on a different date, when HKSE fully functioning, market response would have been much better. In that case, HKSE trading would have taken the precedence in deciding the true value of the excellent deal.
That equals to more than 55 million ordinary shares! There was a drop in the sp towards end of the trading hours. If the majority of the trades were ‘offloading’ of any kind, sp at HKSE and AIM should have plummeted. Today has been another large volume trading (12 million ) at HKSE. HCM sp in AIM market has been in green zone, so far. Any interesting reasons behind the massive volumes?